Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A confirmatory study of masitinib in the treatment of Amyotrophic Lateral Sclerosis

Trial Profile

A confirmatory study of masitinib in the treatment of Amyotrophic Lateral Sclerosis

Planning
Phase of Trial: Phase III

Latest Information Update: 08 May 2018

At a glance

  • Drugs Masitinib (Primary)
  • Indications Amyotrophic lateral sclerosis
  • Focus Registrational; Therapeutic Use
  • Sponsors AB Science
  • Most Recent Events

    • 08 May 2018 New trial record
    • 30 Apr 2018 According to an AB Science media release, the company is planning to conduct this trial to confirm the results of a pivotal study (see profile 700236557) even in case of positive opinion by the CHMP, in case of a conditional marketing authorization application. The company will initiate the trial in 2018 and the results are expected by the beginning of 2021.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top